RGS@Home: Personalized 24/7 Home Care Post-stroke

Status Recruiting

Clinical Trial Summary

Stroke represents one of the main causes of adult disability and will be one of the main contributors to the burden of disease in 2030. However, the healthcare systems are not able to respond to the current demand let alone its future increase. There is a need to deploy new approaches that advance current rehabilitation methods and enhance their efficiency. One of the latest approaches used for the rehabilitation of a wide range of deficits of the nervous system is based on virtual reality (VR) applications, which combine training scenarios with dedicated interface devices. Market drivers exist for new ICT based treatment solutions. IBEC/ Eodyne Systems has developed and commercialised the Rehabilitation Gaming System (RGS), a science-based ICT solution for neurorehabilitation combining brain theory, AI, cloud computing and virtual reality and targeting motor and cognitive recovery after stroke. RGS provides a continuum of evaluations and therapeutic solutions that accompany the patient from the clinic to the therapy centre. RGS has been clinically validated showing its superiority over other products while reducing cost also through its use of standard off-the-shelf hardware and a Software as a Service model (SaaS). Commercial evaluations have shown that RGS acts as a workforce multiplier while delivering a high quality of care at clinical centres (RGS@Clinic). However, in order to achieve significant benefits in the patients' QoL, it is essential that RGS becomes an at home solution providing 24/7 monitoring and care. For this reason, this project aims at investigating the RGS acceptability and adoption model. The findings derived from this study will contribute to establish a novel and superior neurorehabilitation paradigm that can accelerate the recovery of hemiparetic stroke patients. Besides the clinical impact, such achievement could have relevant socioeconomic impact.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04620707
Study type	Interventional
Source	Institute for Bioengineering of Catalonia
Contact	Paul Verschure, PhD
Phone	+34934011918
Email	paul.verschure@specs-lab.com
Status	Recruiting
Phase	N/A
Start date	November 9, 2020
Completion date	July 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05378035` - DOAC in Chinese Patients With Atrial Fibrillation
Completed	`NCT03679637` - Tablet-based Aphasia Therapy in the Acute Phase After Stroke	N/A
Completed	`NCT03574038` - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke	N/A
Completed	`NCT03633422` - Evaluation of Stroke Patient Screening
Completed	`NCT04088578` - VNS-supplemented Motor Retraining After Stroke	N/A
Not yet recruiting	`NCT05534360` - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Not yet recruiting	`NCT04105322` - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients	N/A
Withdrawn	`NCT05786170` - ERILs Und SNILs Unter SOC	N/A
Recruiting	`NCT03132558` - Contrast Induced Acute Kidney in Patients With Acute Stroke	N/A
Completed	`NCT02893631` - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting	`NCT02274727` - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed	`NCT02225730` - Imaging Collaterals in Acute Stroke (iCAS)
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Active, not recruiting	`NCT01581502` - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Completed	`NCT00761982` - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.	Phase 1/Phase 2
Completed	`NCT00535197` - Autologous Bone Marrow Stem Cells in Ischemic Stroke.	Phase 1/Phase 2
Terminated	`NCT00132509` - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke	Phase 2
Recruiting	`NCT05760326` - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.